OBJECTIVES: Since October 2013, the Haute Autorité de Santé (HAS) requires cost-effectiveness evidence to assess innovative health technologies. For cost-utility assessments, the HAS strongly recommends using French utility values. To date, the EQ-5D-3L and the HUI3 are the only instruments with a set of preferences values obtained from a representative sample of the French population. In order to inform a cost-utility model assessing pharmaceutical treatments of previously-treated iNHL, this study aimed to review available utility values in France and to collect such estimates if necessary. METHODS: First, a reproducible MEDLINE search was undertaken to identify studies documenting utility values of previously treated iNHL and CLL in France. Then, a web-survey including socio-demographic and clinical questions as well as the EQ-5D-3L was conducted. Given the difficulty to recruit patients from the target population, the questionnaire was conducted in France, the United Kingdom, Germany, Italy and Spain. In line with the HAS guidelines, French tariffs from Chevalier et al. were applied to the collected EQ-5D data. Mean utility values were generated by health state: progression free and progressive disease.    RESULTS: Only one French cost-utility model conducted by Deconinck E. et al was identified as relevant, but the study used English utility inputs previously published by Wild et al. Results from the EQ-5D-3L questionnaire conducted, illustrated that quality of life was substantially higher in patients with stable disease versus patients with progression disease. Utilities were calculated with the following scoring function, U(E) = 1–u1-u2-u3-u4-u5–N3. Values between u1 to u5 depending of the 3 levels of the 5 dimensions: u1=0;0.15;0.37, u2=0;0.21;.32; u3=0;0.16;0.19; u4=0;0.11;.026; u5=0;0.09;0.20 and N3=0.17. CONCLUSIONS: EQ-5D is a standardised and validated generic instrument which can be used to elicit utility in iNHL patients. To our knowledge, these French utilities of previously-treated iNHL patients are the first to be published.